156 related articles for article (PubMed ID: 17982910)
1. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis.
Rajda C; Bergquist J; Vécsei L
J Neural Transm Suppl; 2007; (72):323-9. PubMed ID: 17982910
[TBL] [Abstract][Full Text] [Related]
2. The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.
Füvesi J; Rajda C; Bencsik K; Toldi J; Vécsei L
J Neural Transm (Vienna); 2012 Feb; 119(2):225-34. PubMed ID: 22258797
[TBL] [Abstract][Full Text] [Related]
3. Neurodegeneration in autoimmune CNS inflammation.
Herz J; Zipp F; Siffrin V
Exp Neurol; 2010 Sep; 225(1):9-17. PubMed ID: 19961850
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines.
Fakan B; Szalardy L; Vecsei L
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669473
[TBL] [Abstract][Full Text] [Related]
5. Antioxidant therapy in multiple sclerosis.
Mirshafiey A; Mohsenzadegan M
Immunopharmacol Immunotoxicol; 2009; 31(1):13-29. PubMed ID: 18763202
[TBL] [Abstract][Full Text] [Related]
6. Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives.
Biernacki T; Sandi D; Bencsik K; Vécsei L
Cells; 2020 Jun; 9(6):. PubMed ID: 32604956
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction related to cell damage induced by 3-hydroxykynurenine and 3-hydroxyanthranilic acid: Non-dependent-effect of early reactive oxygen species production.
Reyes-Ocampo J; Ramírez-Ortega D; Cervantes GI; Pineda B; Balderas PM; González-Esquivel D; Sánchez-Chapul L; Lugo-Huitrón R; Silva-Adaya D; Ríos C; Jiménez-Anguiano A; Pérez-de la Cruz V
Neurotoxicology; 2015 Sep; 50():81-91. PubMed ID: 26254737
[TBL] [Abstract][Full Text] [Related]
8. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.
Zamvil SS; Steinman L
Neuron; 2003 Jun; 38(5):685-8. PubMed ID: 12797954
[TBL] [Abstract][Full Text] [Related]
9. Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis.
Chiarugi A; Cozzi A; Ballerini C; Massacesi L; Moroni F
Neuroscience; 2001; 102(3):687-95. PubMed ID: 11226705
[TBL] [Abstract][Full Text] [Related]
10. Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod.
Majlath Z; Annus A; Vecsei L
Curr Drug Targets; 2018; 19(7):805-814. PubMed ID: 28017129
[TBL] [Abstract][Full Text] [Related]
11. HIV-Tat-mediated Bcl-XL delivery protects retinal ganglion cells during experimental autoimmune optic neuritis.
Diem R; Taheri N; Dietz GP; Kuhnert A; Maier K; Sättler MB; Gadjanski I; Merkler D; Bähr M
Neurobiol Dis; 2005 Nov; 20(2):218-26. PubMed ID: 16242630
[TBL] [Abstract][Full Text] [Related]
12. Future neuroprotective strategies.
Sättler MB; Bähr M
Exp Neurol; 2010 Sep; 225(1):40-7. PubMed ID: 19716365
[TBL] [Abstract][Full Text] [Related]
13. Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant.
Binyamin O; Larush L; Frid K; Keller G; Friedman-Levi Y; Ovadia H; Abramsky O; Magdassi S; Gabizon R
Int J Nanomedicine; 2015; 10():7165-74. PubMed ID: 26648720
[TBL] [Abstract][Full Text] [Related]
14. Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.
Sandi D; Fricska-Nagy Z; Bencsik K; Vécsei L
Molecules; 2021 Jun; 26(11):. PubMed ID: 34198750
[TBL] [Abstract][Full Text] [Related]
15. Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System.
Rajda C; Majláth Z; Pukoli D; Vécsei L
Int J Mol Sci; 2015 Aug; 16(8):18270-82. PubMed ID: 26287161
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the kynurenine pathway.
Stone TW
Eur J Med Chem; 2000 Feb; 35(2):179-86. PubMed ID: 10758280
[TBL] [Abstract][Full Text] [Related]
17. Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis.
Willenborg DO; Staykova MA
Adv Exp Med Biol; 2003; 520():96-119. PubMed ID: 12613575
[No Abstract] [Full Text] [Related]
18. Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis.
Chitnis T; Imitola J; Khoury SJ
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Mar; 5(1):11-26. PubMed ID: 15777201
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the evidence for multiple sclerosis as an autoimmune disease.
Altmann D
Arch Neurol; 2005 Apr; 62(4):688; author reply 688-9. PubMed ID: 15824275
[No Abstract] [Full Text] [Related]
20. Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies.
Sundaram G; Brew BJ; Jones SP; Adams S; Lim CK; Guillemin GJ
J Neuroinflammation; 2014 Dec; 11():204. PubMed ID: 25498310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
